Condition: Obstructive Hypertrophic Cardiomyopathy (oHCM) · Sponsor: China National Center for Cardiovascular Diseases
This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study will recruit patients with oHCM who, under double-blind conditions, will be randomly assigned to either the Ademetionine group or the placebo group. Follow-up visits will be conducted every 4 weeks until 16 weeks from baseline. After 16 weeks, the study will evaluating the effect of Ademetionine on exercise capacity, heart failure symptoms, cardiac structure and function, and quality of life, as well as safety and tolerability of Ademetionine in this patient population.
This description comes directly from the study's public registry record.
Yu Zhang · +86 19801288531 · dr_yuzhang@126.com
Always discuss trial participation with your own doctor first.
| Fuwai Hospital | Beijing, China | Recruiting |
| Zhongshan Hospital, Shanghai Medical College of Fudan University | Shanghai, China | Recruiting |
| The First Affiliated Hospital of Xinjiang Medical University | Xinjiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07367724